Orbis Medicines’ Series A round of funding was led by New Enterprise Associates. The startup is developing oral macrocyclic drugs for targets validated by blockbuster biologic medications that must be administered by injection.
The post A Startup’s €90M Financing for Oral Peptide Drugs Includes Backing from Eli Lilly appeared first on MedCity News.
